Study of camrelizumab or famitinib for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at how well camrelizumab or famitinib (alone or with other drugs) work for cervical cancer. It may help doctors understand better treatments for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have cervical cancer confirmed by a tissue sample (biopsy).
- You must be taking or about to take camrelizumab or famitinib, alone or with other drugs.
- If you can become pregnant, you must agree to use effective birth control and avoid donating eggs during the study and for up to 3 months after treatment ends.
- You cannot be pregnant or breastfeeding.
- You should not be in any other research study that involves treatments outside of standard care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different doses of the oral drug famitinib combined with the immunotherapy camrelizumab in people whose cervical cancer has come back or spread and can no longer be treated with standard therapies. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, camrelizumab and famitinib, given after surgery to remove cervical cancer. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This trial tests a combination of two drugs—camrelizumab (an immunotherapy) and famitinib (a targeted therapy)—for people with rare head and neck tumors that cannot be removed by surgery or have spread. It may be an option if you have not had a prior PD-1 inhibitor and have had at most one prior systemic treatment.
This trial tests whether giving chemotherapy combined with camrelizumab (a drug that helps the immune system fight cancer) before surgery can help women with early-stage cervical cancer who want to preserve their fertility. It is for patients whose tumors show a protein called PD-L1.
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
Hear when a new Cervical Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.